SAB Biotherapeutics
SABS
40 hedge funds and large institutions have $2.32M invested in SAB Biotherapeutics in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
8% more funds holding
Funds holding: 37 → 40 (+3)
0.05% more ownership
Funds ownership: 0.72% → 0.77% (+0.05%)
48% less capital invested
Capital invested by funds: $4.45M → $2.32M (-$2.13M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FPB
First PREMIER Bank
Sioux Falls,
South Dakota
|
+$154K |
| 2 |
IFAM
Institutional & Family Asset Management
Fort Collins,
Colorado
|
+$71.1K |
| 3 |
Mariner
Overland Park,
Kansas
|
+$68.5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$39.9K |
| 5 |
Jane Street
New York
|
+$23.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SOS
Silver Oak Securities
Jackson,
Tennessee
|
-$64K |
| 2 |
MC
Meteora Capital
Boca Raton,
Florida
|
-$42.7K |
| 3 |
Millennium Management
New York
|
-$25.5K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$20.5K |
| 5 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$19K |
SABS Hedge Fund Activity: Q3 2022 in Review
40 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q3 2022, worth a combined $2.32M — down 48% from $4.45M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new SABS positions and 3 closed out — a net gain of 3 holders — while 10 added to existing stakes and 8 trimmed.
The largest buyer was First PREMIER Bank, adding an estimated $154K. The largest seller was Silver Oak Securities, exiting entirely with an estimated $64K sold.
- 40 institutional investors held SAB Biotherapeutics (SABS) as of Q3 2022, up from 37 in Q2 2022.
- Funds reported $2.32M of SAB Biotherapeutics stock for Q3 2022, down 48% quarter-over-quarter.
- 6 funds opened new SAB Biotherapeutics positions in Q3 2022 and 3 closed out, a net change of +3 holders.
- The largest SAB Biotherapeutics buyer in Q3 2022 was First PREMIER Bank, an estimated $154K added.
- The largest SAB Biotherapeutics seller in Q3 2022 was Silver Oak Securities, an estimated $64K sold.
Based on aggregated 13F filings for Q3 2022.